VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

L. major H1 Protein Vaccine
Vaccine Information
  • Vaccine Name: L. major H1 Protein Vaccine
  • Target Pathogen: Leishmania major
  • Target Disease: Cutaneous leishmaniasis
  • Vaccine Ontology ID: VO_0004176
  • Type: Subunit vaccine
  • Status: Research
  • SW3.1 gene engineering:
    • Type: Recombinant protein preparation
    • Description: Recombinant H1 protein (Solioz et al., 1999)
    • Detailed Gene Information: Click Here.
  • Adjuvant: incomplete Freunds adjuvant
  • Immunization Route: Subcutaneous injection
Host Response

Mouse Response

  • Host Strain: BALB/c, C57BL/6 or B10.D2
  • Vaccination Protocol: In all protection experiments, mice (n=5–8) were given injections (2×25 μl) of antigen preparation twice subcutaneously (s.c.) at the base of the tail. Before the injection, antigens were either emusified in IFA (1:1, vol/vol), mixed (1:1, vol/vol) with either 0.5 or 1 μg of IL-12 in PBS or prepared in PBS only. Several doses of antigen were tested and parasite challenge in the right hind footpad was performed at different time points after the second injection (Solioz et al., 1999).
  • Challenge Protocol: In this long term experiment, mice were challenged two and a half months after the second injection of antigen with 2×106 highly infectious parasites (Solioz et al., 1999).
  • Efficacy: When inoculated in the presence of IFA as adjuvant, the partially purified histone H1 was able to confer partial protection in six out of eight mice (Solioz et al., 1999).
References
Solioz et al., 1999: Solioz N, Blum-Tirouvanziam U, Jacquet R, Rafati S, Corradin G, Mauël J, Fasel N. The protective capacities of histone H1 against experimental murine cutaneous leishmaniasis. Vaccine. 1999; 18(9-10); 850-859. [PubMed: 10580198].